Scarica l'app Stockscreener
13.08
1.51%
-0.20
Dopo l'orario di chiusura:
13.34
0.26
+1.99%
Precedente Chiudi:
$13.28
Aprire:
$13.32
Volume 24 ore:
695.24K
Relative Volume:
4.82
Capitalizzazione di mercato:
$1.67B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+16.68%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$12.80
$13.70
Intervallo di 1 settimana:
$11.60
$13.70
Portata 52W:
$11.00
$13.95
Generate Biomedicines Inc Stock (GENB) Company Profile
Nome
Generate Biomedicines Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare GENB vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
13.08 | 1.67B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Generate Biomedicines Inc Borsa (GENB) Ultime notizie
GENB News Today | Why did Generate Biomedicines stock go down today? - MarketBeat
Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat
Generate Biomedicines (GENB) 10K Form and SEC Filings 2026 - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Return on assets % of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Goodwin Advises Generate Biomedicines, Inc. On The Closing Of Its $400 Million Initial Public Offering - Mondaq
Generate Biomedicines (GENB) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Generate Biomedicines IPO Opens Nasdaq Chapter And Investor Watch Period - simplywall.st
GENB Stock Price, News & Analysis - Stock Titan
Generate Biomedicines, Inc. Income Statement – BOATS:GENB - TradingView
Generate Biomedicines, Inc. (GENB) Stock Live Price, Chart & News - CoinCodex
GENB PE Ratio & Valuation, Is GENB Overvalued - Intellectia AI
GENB | Generate Biomedicines, Inc. Common Institutional Ownership - Quiver Quantitative
GENB | Generate Biomedicines, Inc. Common Insider Trading - Quiver Quantitative
Insider Buying: Jane Mendillo Acquires Shares in Generate Biomed - GuruFocus
GENB: Static price chart | Generate Biomedicines, Inc. | US3709201004 - marketscreener.com
Assessing Generate Biomedicines (GENB) Valuation After Recent Share Price Volatility - Sahm
Generate Biomedicines amends charter and bylaws ahead of Nasdaq IPO By Investing.com - Investing.com UK
Executive at Generate Biomedicines (GENB) awarded 190,034 stock options - Stock Titan
Generate Biomedicines (GENB) CEO adds options and IPO conversion shares - Stock Titan
Generate Biomedicines amends charter and bylaws ahead of Nasdaq IPO - Investing.com
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent
Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug - Dealbreaker
Generate IPO raises $400 million but shares sink - The Pharma Letter
Generate Biomedicines (GENB) CMO awarded 42,230 stock options vesting over 4 years - Stock Titan
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to NASDAQ Composite Index - marketscreener.com
EBITDA of GENERATE BIOMEDICINES INC – NASDAQ:GENB - TradingView
Generate Biomedicines shares fall in weak Nasdaq debut for drug developer - WSAU
Generate Biomedicines prices IPO at $16 per share By Investing.com - Investing.com Australia
Generate Biomedicines Shares Plummet After $400 Million Market Debut - WSJ
U.S. IPO Weekly Recap: Asthma-Focused Generate Biomedicines Closes Out February IPO Market - Seeking Alpha
IPO NewsUS IPO Weekly Recap: Asthma-focused Generate Biomedicines closes out February IPO market - renaissancecapital.com
AI-Focused Generate Biomedicines Prices $400M IPO - Law360
Generate Biomedicines, AI-Driven Generative Biology Drug Developer, Files for Nasdaq Global Select Market IPO - TradingView
Generate Biomedicines Share Price Target and Forecast - Investing.com India
Generate Biomedicines stock opens below IPO price in Nasdaq debut By Investing.com - Investing.com South Africa
Generate Biomedicines stock opens below IPO price in Nasdaq debut - Investing.com
Generate Biomedicines Shares Fall After Nasdaq Debut - marketscreener.com
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut - AOL.com
Generate Biomedicines-Aktien fallen bei schwachem Nasdaq-Debüt des Arzneimittelentwicklers - TradingView
Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer - TradingView
Shares of Generate Biomedicines open at $15 in their Nasdaq debut vs $16 IPO price - marketscreener.com
TSLP still plays well, Generates $400M IPO - BioWorld MedTech
Generate Biomedicines, Inc. share price - Capital.com
AI-driven drug developer nets $400M IPO, matching 2020 record - The Business Journals
Generate’s $400m IPO Adds To Biotech Bounceback - Citeline News & Insights
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and more - Medical Marketing and Media
Trade Generate Biomedicines, Inc.GENB CFD - Capital.com
Generate:Biomedicines Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Generate:Biomedicines Rings the Opening Bell - Nasdaq
Generate Biomedicines Inc Azioni (GENB) Dati Finanziari
Non sono disponibili dati finanziari per Generate Biomedicines Inc (GENB). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):